-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$28.50262.6% Upside
Olema Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Olema Pharmaceuticals, Inc.?
Olema Pharmaceuticals, Inc. has been rated by research analysts at Goldman Sachs, H.C. Wainwright in the past 90 days.